Creative Medical Technology (NASDAQ:CELZ) Announces Earnings Results

Creative Medical Technology (NASDAQ:CELZ) issued its quarterly earnings results on Friday. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.49), Zacks reports.

Creative Medical Technology Stock Up 9.0 %

Creative Medical Technology stock traded up $0.27 during trading hours on Friday, reaching $3.27. 155,245 shares of the company’s stock were exchanged, compared to its average volume of 37,240. The firm’s 50 day simple moving average is $3.69 and its 200 day simple moving average is $3.28. Creative Medical Technology has a twelve month low of $1.96 and a twelve month high of $6.90. The firm has a market capitalization of $7.60 million, a PE ratio of -0.86 and a beta of 1.70.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.